A Phase 1 Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF Mutations.
Phase of Trial: Phase I
Latest Information Update: 02 May 2013
At a glance
- Drugs ARQ 736 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacogenomic
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 Jul 2012 Planned End Date changed from 1 Feb 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
- 20 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.